Post-COVID-19 deep vein thrombosis and its pharmacological management

Detalhes bibliográficos
Autor(a) principal: Muguet, Clara Maria
Data de Publicação: 2022
Outros Autores: Guimarães, Karoline, Bastos, Lilian, Baroni, Marcela, Curty, Marcela, Marzano, Marcos, Costa, Mariana, Tardelli, Mirela, Risi , Rafael, Lustosa , Renata, Estato, Vanessa
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
DOI: 10.33448/rsd-v11i1.24991
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/24991
Resumo: Infection caused by the SARS-CoV-2 coronavirus presents clinical cases that range from asymptomatic to severe. Even in milder cases, sequelae related to a hypercoagulable state associated with COVID-19 can be observed, with an increased prevalence of Venous Thromboembolism (VTE). The occurrence of VTE is higher in patients, mainly patients hospitalized in intensive care units and requires anticoagulation therapy, however, post-COVID thrombogenesis can also occur at a later stage, in the absence of viral load. The prothrombotic mechanisms related to SARS-CoV-2 differ with regard to the use of antiplatelet and anticoagulant drugs in patients with suspected or confirmed COVID-19. The pharmacology and clinical applicability of anticoagulant drugs such as heparins and oral anticoagulants will be described in this study. This study is an exploratory study aiming to address issues related to the treatment hitherto recommended for thrombotic events in patients affected by COVID-19.
id UNIFEI_00ad4aad524fdec905ac72ab8cb0097a
oai_identifier_str oai:ojs.pkp.sfu.ca:article/24991
network_acronym_str UNIFEI
network_name_str Research, Society and Development
spelling Post-COVID-19 deep vein thrombosis and its pharmacological managementTrombosis venosa profunda post-COVID-19 y su manejo farmacológicoA trombose venosa profunda pós-COVID-19 e seu manejo farmacológicoSARS-CoV-2COVID-19AnticoagulantsVenous thromboembolism.SARS-CoV-2COVID-19AnticoagulantesTromboembolia venosa.SARS-CoV-2COVID-19AnticoagulantesTromboembolia venosa.Infection caused by the SARS-CoV-2 coronavirus presents clinical cases that range from asymptomatic to severe. Even in milder cases, sequelae related to a hypercoagulable state associated with COVID-19 can be observed, with an increased prevalence of Venous Thromboembolism (VTE). The occurrence of VTE is higher in patients, mainly patients hospitalized in intensive care units and requires anticoagulation therapy, however, post-COVID thrombogenesis can also occur at a later stage, in the absence of viral load. The prothrombotic mechanisms related to SARS-CoV-2 differ with regard to the use of antiplatelet and anticoagulant drugs in patients with suspected or confirmed COVID-19. The pharmacology and clinical applicability of anticoagulant drugs such as heparins and oral anticoagulants will be described in this study. This study is an exploratory study aiming to address issues related to the treatment hitherto recommended for thrombotic events in patients affected by COVID-19.La infección causada por el coronavirus SARS-CoV-2 presenta casos clínicos que van desde asintomáticos hasta graves. Incluso en casos leves, se pueden observar secuelas relacionadas con un estado de hipercoagulabilidad asociado a COVID-19, con una mayor prevalencia de tromboembolismo venoso (TEV). La aparición de TEV es mayor en pacientes, principalmente pacientes hospitalizados en unidades de cuidados intensivos y requiere tratamiento anticoagulante, sin embargo, la trombogénesis post-COVID también puede ocurrir en una etapa posterior, en ausencia de carga viral. Los mecanismos protrombóticos relacionados con el SARS-CoV-2 difieren con respecto al uso de fármacos antiplaquetarios y anticoagulantes en pacientes con COVID-19 sospechado o confirmado. En este estudio se describirán la farmacología y la aplicabilidad clínica de los fármacos anticoagulantes como las heparinas y los anticoagulantes orales. Este estudio es un estudio exploratorio que tiene como objetivo abordar cuestiones relacionadas con el tratamiento hasta ahora recomendado para eventos trombóticos en pacientes afectados por COVID-19.A infecção causada pelo coronavírus SARS-CoV-2 apresenta casos clínicos que variam de assintomáticos para graves. Mesmo nos casos mais brandos, podem ser observadas sequelas relacionadas a um estado hipercoagulável associado à COVID-19, com a prevalência aumentada de Tromboembolismo Venoso (TEV). A ocorrência de TEV é maior principalmente em pacientes internados em unidades de terapia intensiva e requer terapia de anticoagulação, no entanto, a trombogênse pós-COVID também pode ocorrer numa fase mais tardia, na ausência de carga viral. Os mecanismos pró-trombóticos relacionados ao SARS-CoV-2 apresentam divergências no que se refere ao uso de medicamentos antiplaquetários e anticoagulantes em pacientes com suspeita ou confirmação de COVID-19. A farmacologia e a aplicabilidade clínica dos fármacos anticoagulantes como as heparinas e os anticoagulantes orais, serão descritas neste estudo. Este estudo é um estudo exploratório com o objetivo de abordar as questões relacionadas ao tratamento farmacológico e os mecanismos de ação dos fármacos até então recomendados para o tratamento e profilaxia dos eventos trombóticos em pacientes acometidos pela COVID-19.Research, Society and Development2022-01-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2499110.33448/rsd-v11i1.24991Research, Society and Development; Vol. 11 No. 1; e12311124991Research, Society and Development; Vol. 11 Núm. 1; e12311124991Research, Society and Development; v. 11 n. 1; e123111249912525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/24991/21733Copyright (c) 2022 Clara Maria Muguet; Karoline Guimarães; Lilian Bastos; Marcela Baroni; Marcela Curty; Marcos Marzano; Mariana Costa; Mirela Tardelli; Rafael Risi ; Renata Lustosa ; Vanessa Estatohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMuguet, Clara Maria Guimarães, KarolineBastos, Lilian Baroni, Marcela Curty, MarcelaMarzano, MarcosCosta, MarianaTardelli, Mirela Risi , Rafael Lustosa , RenataEstato, Vanessa 2022-01-16T18:08:18Zoai:ojs.pkp.sfu.ca:article/24991Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:43:22.858692Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Post-COVID-19 deep vein thrombosis and its pharmacological management
Trombosis venosa profunda post-COVID-19 y su manejo farmacológico
A trombose venosa profunda pós-COVID-19 e seu manejo farmacológico
title Post-COVID-19 deep vein thrombosis and its pharmacological management
spellingShingle Post-COVID-19 deep vein thrombosis and its pharmacological management
Post-COVID-19 deep vein thrombosis and its pharmacological management
Muguet, Clara Maria
SARS-CoV-2
COVID-19
Anticoagulants
Venous thromboembolism.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
Muguet, Clara Maria
SARS-CoV-2
COVID-19
Anticoagulants
Venous thromboembolism.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
title_short Post-COVID-19 deep vein thrombosis and its pharmacological management
title_full Post-COVID-19 deep vein thrombosis and its pharmacological management
title_fullStr Post-COVID-19 deep vein thrombosis and its pharmacological management
Post-COVID-19 deep vein thrombosis and its pharmacological management
title_full_unstemmed Post-COVID-19 deep vein thrombosis and its pharmacological management
Post-COVID-19 deep vein thrombosis and its pharmacological management
title_sort Post-COVID-19 deep vein thrombosis and its pharmacological management
author Muguet, Clara Maria
author_facet Muguet, Clara Maria
Muguet, Clara Maria
Guimarães, Karoline
Bastos, Lilian
Baroni, Marcela
Curty, Marcela
Marzano, Marcos
Costa, Mariana
Tardelli, Mirela
Risi , Rafael
Lustosa , Renata
Estato, Vanessa
Guimarães, Karoline
Bastos, Lilian
Baroni, Marcela
Curty, Marcela
Marzano, Marcos
Costa, Mariana
Tardelli, Mirela
Risi , Rafael
Lustosa , Renata
Estato, Vanessa
author_role author
author2 Guimarães, Karoline
Bastos, Lilian
Baroni, Marcela
Curty, Marcela
Marzano, Marcos
Costa, Mariana
Tardelli, Mirela
Risi , Rafael
Lustosa , Renata
Estato, Vanessa
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Muguet, Clara Maria
Guimarães, Karoline
Bastos, Lilian
Baroni, Marcela
Curty, Marcela
Marzano, Marcos
Costa, Mariana
Tardelli, Mirela
Risi , Rafael
Lustosa , Renata
Estato, Vanessa
dc.subject.por.fl_str_mv SARS-CoV-2
COVID-19
Anticoagulants
Venous thromboembolism.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
topic SARS-CoV-2
COVID-19
Anticoagulants
Venous thromboembolism.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
SARS-CoV-2
COVID-19
Anticoagulantes
Tromboembolia venosa.
description Infection caused by the SARS-CoV-2 coronavirus presents clinical cases that range from asymptomatic to severe. Even in milder cases, sequelae related to a hypercoagulable state associated with COVID-19 can be observed, with an increased prevalence of Venous Thromboembolism (VTE). The occurrence of VTE is higher in patients, mainly patients hospitalized in intensive care units and requires anticoagulation therapy, however, post-COVID thrombogenesis can also occur at a later stage, in the absence of viral load. The prothrombotic mechanisms related to SARS-CoV-2 differ with regard to the use of antiplatelet and anticoagulant drugs in patients with suspected or confirmed COVID-19. The pharmacology and clinical applicability of anticoagulant drugs such as heparins and oral anticoagulants will be described in this study. This study is an exploratory study aiming to address issues related to the treatment hitherto recommended for thrombotic events in patients affected by COVID-19.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-03
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24991
10.33448/rsd-v11i1.24991
url https://rsdjournal.org/index.php/rsd/article/view/24991
identifier_str_mv 10.33448/rsd-v11i1.24991
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24991/21733
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 1; e12311124991
Research, Society and Development; Vol. 11 Núm. 1; e12311124991
Research, Society and Development; v. 11 n. 1; e12311124991
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1822178477074284544
dc.identifier.doi.none.fl_str_mv 10.33448/rsd-v11i1.24991